Assessments of relative efficacy , effectiveness , safety ( serious adverse events ) , and immunogenicity ( hemagglutination-inhibition -LSB- HAI -RSB- titers ) were performed during the @-@ ( year @ ) and the @-@ ( year @ ) northern-hemisphere influenza seasons .